Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.56M Sell
27,689
-654
-2% -$76.5K 0.26% 75
2026
Q1
$3.41M Buy
28,343
+37
+0.1% +$4.27K 0.27% 74
2025
Q4
$2.98M Sell
28,306
-2,350
-8% -$221K 0.24% 86
2025
Q3
$2.57M Buy
30,656
+360
+1% +$29.7K 0.21% 100
2025
Q2
$2.4M Buy
30,296
+592
+2% +$47.1K 0.21% 100
2025
Q1
$2.67M Buy
29,704
+2,735
+10% +$255K 0.26% 88
2024
Q4
$2.68M Buy
26,969
+102
+0.4% +$10.5K 0.26% 85
2024
Q3
$3.05M Buy
26,867
+321
+1% +$38.1K 0.31% 80
2024
Q2
$3.29M Sell
26,546
-74
-0.3% -$9.53K 0.38% 63
2024
Q1
$3.51M Buy
26,620
+851
+3% +$105K 0.45% 47
2023
Q4
$2.81M Sell
25,769
-1,321
-5% -$137K 0.39% 68
2023
Q3
$2.79M Buy
27,090
+1,241
+5% +$134K 0.38% 67
2023
Q2
$2.98M Buy
25,849
+2,248
+10% +$255K 0.43% 62
2023
Q1
$2.51M Buy
23,601
+1,635
+7% +$177K 0.4% 68
2022
Q4
$2.44M Buy
21,966
+7,125
+48% +$728K 0.43% 59
2022
Q3
$1.28M Buy
14,841
+2,933
+25% +$262K 0.32% 88
2022
Q2
$1.09M Buy
+11,908
New +$1.06M 0.31% 84
2021
Q3
Sell
-3,781
Closed -$294K 203
2021
Q2
$294K Buy
3,781
+184
+5% +$13.7K 0.09% 173
2021
Q1
$265K Hold
3,597
0.1% 173
2020
Q4
$281K Buy
+3,597
New +$275K 0.11% 164

Other funds holding MRK

CGN Advisors's MRK Position: Q2 2026 in Review

CGN Advisors reduced its Merck (MRK) stake by 2.3% in Q2 2026, selling an estimated $76.5K and leaving 27,689 shares worth $3.56M. The position accounts for 0.26% of the portfolio, ranked #75.

CGN Advisors first reported a position in MRK in Q4 2020 and has held it in 20 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • CGN Advisors held 27,689 shares of Merck worth $3.56M as of Q2 2026.
  • CGN Advisors sold 654 Merck shares in Q2 2026, an estimated $76.5K.
  • Merck made up 0.26% of CGN Advisors's portfolio in Q2 2026, its #75 holding.
  • CGN Advisors first reported a position in Merck in Q4 2020 and has held it in 20 quarters since.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on CGN Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.